Generate Biomedicines (GENB)

Type: Public AI drug discovery company (biologics focus) — NASDAQ: GENB — Flagship Pioneering spinout

Generate Biomedicines develops protein-based therapeutics using its Chroma generative AI platform, which was the first published demonstration of all-atom protein generation conditioned on arbitrary functional specifications (Nature, 2023). The company applies Chroma to design biologics (antibodies, proteins, multi-domain constructs) across oncology and immunology.

IPO (February 2026)

• IPO date: February 26, 2026
• Price: $16/share (midpoint of $15–17 range)
• Shares: 25 million shares sold
• Gross proceeds: $400 million
• Exchange: NASDAQ, ticker GENB
• Significance: Largest biotech IPO of the year at time of pricing; validated the public market appetite for AI-native biologics companies. (BioPharma Dive, OncoDaily)

Lead Program

• GB-0895 — anti-TSLP antibody for severe asthma; Phase 3 studies. The program is the clinical execution test of the Chroma platform.

Key deal

• Novartis partnership (~$1B+ milestones) — Announced September 2024; co-development of Chroma-designed protein therapeutics. (IntuitionLabs biologics trends)

What to watch

• Phase 3 readout for GB-0895 — validates that AI-designed antibody can beat a clinical bar
• Whether Chroma platform generates additional pipeline beyond the lead program post-IPO
• Post-IPO execution under public market scrutiny (cash runway management)